Kronik hepatit C'ye bağlı karaciğer transplantasyonu yapılan hastalarda transplantasyon sonrası ledipasvir/sofosbuvir tedavisinin etkinliği
Küçük Resim Yok
Tarih
2018
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Giriş: Bu çalışmada; kronik HCV'ye sekonder siroz gelişen ve sonrasında karaciğer transplantasyonu yapılmış olan hastalarda, HCV enfeksiyonunun nüksüne yönelik yeni geliştirilmiş DEA ilaç grubundan LDV-SOF kombinasyon tedavisinin etkinliği araştırıldı. Materyal ve Metodlar: İnönü Üniversitesi Turgut Özal Tıp Merkezi Gastoenteroloji Bilim Dalı'nda 01.01.2008 - 31.12.2017 tarihleri arasında kronik HCV'ye bağlı siroz nedeniyle karaciğer transplantasyonu yapılan, transplantasyon sonrasında 01.01.2016 - 31.12.2017 tarihleri arasında 12 hafta boyunca LDV-SOF tedavisi alan 27 hasta dosyası retrospektif olarak incelendi. Bulgular: Çalışmaya 20 hasta dahil edildi. Hastaların HCV genotipleri, tedavi başlangıcı ve tedavi sonrasındaki 1.ay, 2.ay, 6.ay HCV-RNA, AST, ALT, ALP, GGT, total bilirubin, albümin, INR, HGB ve PLT düzeyleri çalışıldı. 6.ay sonunda hastaların tamamında HCV-RNA düzeyleri ölçülemeyecek düzeye gelmiş olup, AST, ALT ve GGT düzeylerinde anlamlı düşüş saptandı (sırasıyla; p<0,001, p<0,001, p<0,001). Hastaların hiçbirinde tedavi kesilmesine sebep olacak bir komplikasyon izlenmedi. Sonuç: Kronik HCV'ye sekonder gelişen siroza bağlı nakil olan ve sonrasında HCV nüksü gözlenen hastaların tedavisinde LDV-SOF kombinasyonu, güvenilir ve yüksek başarı oranı olan bir tedavidir. Anahtar Kelime: DEA, HCV, karaciğer transplantasyonu, LDV-SOF
Introduction: This study investigates the efficacy of LDV-SOF, a newly-developed, DAA drug combination for HCV infection recurrence in patients who have developed cirrhosis secondary to HCV and who have undergone liver transplantations. Material and Method: A total of 27 patients who underwent liver transplantations due to HCV related cirrhosis and who received LDV-SOF for 12 weeks between 01.01.2016 and 31.12.2017 following transplantation at the Inonu University Turgut Ozal Medical Center Gastroenterology Department between 01.01.2008 and 31.12.2017 were evaluated retrospectively. Results: Twenty patients were ultimately included in the present study. HCV genotypes, HCV-RNA, AST, ALT, ALP, GGT, total bilirubin, albumin, INR, HGB and PLT levels of the patients before treatment and at months 1, 2 and 6 were evaluated. At the end of month 6, while the HCV-RNA levels of all patients decreased to unmeasurable levels, levels of AST, ALT and GGT decreased significantly (respectively; p<0,001, p<0,001, p<0,001). None of the patients experienced a complication which led to cessation of treatment. Conclusion: With its reliability and high success rate, the LDV-SOF combination is a strongly preferable treatment for patients who have undergone liver transplantation due to chronic HCV-related cirrhosis and who have HCV recurrence following transplantation. Keywords: DAA, HCV, liver transplantation, LDV-SOF
Introduction: This study investigates the efficacy of LDV-SOF, a newly-developed, DAA drug combination for HCV infection recurrence in patients who have developed cirrhosis secondary to HCV and who have undergone liver transplantations. Material and Method: A total of 27 patients who underwent liver transplantations due to HCV related cirrhosis and who received LDV-SOF for 12 weeks between 01.01.2016 and 31.12.2017 following transplantation at the Inonu University Turgut Ozal Medical Center Gastroenterology Department between 01.01.2008 and 31.12.2017 were evaluated retrospectively. Results: Twenty patients were ultimately included in the present study. HCV genotypes, HCV-RNA, AST, ALT, ALP, GGT, total bilirubin, albumin, INR, HGB and PLT levels of the patients before treatment and at months 1, 2 and 6 were evaluated. At the end of month 6, while the HCV-RNA levels of all patients decreased to unmeasurable levels, levels of AST, ALT and GGT decreased significantly (respectively; p<0,001, p<0,001, p<0,001). None of the patients experienced a complication which led to cessation of treatment. Conclusion: With its reliability and high success rate, the LDV-SOF combination is a strongly preferable treatment for patients who have undergone liver transplantation due to chronic HCV-related cirrhosis and who have HCV recurrence following transplantation. Keywords: DAA, HCV, liver transplantation, LDV-SOF
Açıklama
Anahtar Kelimeler
Gastroenteroloji, Gastroenterology
